27 results on '"Massaro, Fulvio"'
Search Results
2. Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders.
- Author
-
Massaro, Fulvio, Andreozzi, Fabio, Abrassart, Tom, Castiaux, Julie, Massa, Hanne, Rizzo, Ornella, and Vercruyssen, Marie
- Subjects
LYMPHOPROLIFERATIVE disorders ,BISPECIFIC antibodies ,HODGKIN'S disease ,CHIMERIC antigen receptors ,HEMATOLOGIC malignancies - Abstract
Over the past three decades, the treatment of lymphoproliferative disorders has undergone profound changes, notably due to the increasing availability of innovative therapies with the potential to redefine clinical management paradigms. A major impact is related to the development of monoclonal antibodies, checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T (CAR-T) cell therapies. This review discusses the current landscape of clinical trials targeting various hematological malignancies, highlighting promising early-phase results and strategies to overcome resistance. Lymphoproliferative disorders encompass a range of conditions: while in Hodgkin lymphoma (HL) the goal is to reduce chemotherapy-related toxicity by integrating immunotherapy into the frontline setting, peripheral T cell lymphoma (PTCL) lacks effective targeted therapies. The review emphasizes a shifting therapeutic landscape towards precision medicine and treatment modalities that are less toxic yet more effective. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Clinical diagnosis—part I: what is really caused by Chiari I
- Author
-
Ciaramitaro, Palma, Ferraris, Marilena, Massaro, Fulvio, and Garbossa, Diego
- Published
- 2019
- Full Text
- View/download PDF
4. Supportive Care in Older Lymphoma Patients to Reduce Toxicity and Preserve Quality of Life.
- Author
-
Massaro, Fulvio, Andreozzi, Fabio, Vandevoorde, Charlotte, and Bron, Dominique
- Subjects
- *
PREVENTION of drug side effects , *SOCIAL support , *CANCER chemotherapy , *ANTINEOPLASTIC agents , *GERIATRIC assessment , *CANCER patients , *QUALITY of life , *LYMPHOMAS , *DRUG toxicity , *CANCER patient medical care , *IMMUNOTHERAPY , *OLD age - Abstract
Simple Summary: Lymphoproliferative disorders are commonly observed in the elderly population and usually their treatment can cause numerous side effects, loss of autonomy and impaired quality of life. The management of these patients, when a curative treatment is proposed, needs to be personalized according to subject, disease and treatment features. Nowadays, in order to reduce the impact of toxicities, supportive therapy is a crucial ally during the administration of chemo-immunotherapy. Particularly, the prevention of hematological and infectious complications, tumor lysis syndrome and cardiovascular and neurological events could lead not only to improved oncological outcomes but also to improved quality of life. The treatment paradigm in older patients with malignant hemopathies is the choice between an effective conservative treatment that preserves quality of life and an intensive, potentially curative treatment with more toxicities. For each patient, it is important to determine the risk/benefit ratio. The patient should be involved in the discussion, sufficiently informed and able to express himself and his expectations in terms of quality of life. However, this informed consent is conditioned by the ability of the patient to understand the risks and benefits of the treatment. Decline in quality of life is an important parameter for older patients with cancer and many prospective trials have now confirmed the impact of different side effects of treatment, such as recurrent hospitalization, loss of autonomy in daily activities, loss of contact with grandchildren and loss of cognitive functions. Interventions oriented to vulnerabilities detected in the older patients (by comprehensive geriatric assessment) and an optimal approach, including preventive measures to reduce treatment-related toxicity and mortality, are directly correlated to improvement in quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Proposal for a tailored stratification at baseline and monitoring of cardiovascular effects during follow-up in chronic phase chronic myeloid leukemia patients treated with nilotinib frontline
- Author
-
Breccia, Massimo, Arboscello, Eleonora, Bellodi, Andrea, Colafigli, Gioia, Molica, Matteo, Bergamaschi, Micaela, Massaro, Fulvio, Quattrocchi, Luisa, Sarocchi, Matteo, Spallarossa, Paolo, and Alimena, Giuliana
- Published
- 2016
- Full Text
- View/download PDF
6. Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events
- Author
-
Molica, Matteo, Scalzulli, Emilia, Colafigli, Gioia, Fegatelli, Danilo Alunni, Massaro, Fulvio, Latagliata, Roberto, Foà, Robin, and Breccia, Massimo
- Published
- 2018
- Full Text
- View/download PDF
7. Early molecular response in chronic myeloid leukemia and halving time: Latest evidences
- Author
-
Breccia, Massimo, Molica, Matteo, Colafigli, Gioia, Massaro, Fulvio, and Alimena, Giuliana
- Published
- 2016
- Full Text
- View/download PDF
8. Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN
- Author
-
Breccia, Massimo, Andriani, Alessandro, Montanaro, Marco, Abruzzese, Elisabetta, Buccisano, Francesco, Cedrone, Michele, Centra, Antonietta, Villivà, Nicoletta, Celesti, Francesca, Trawinska, Malgorzata Monica, Massaro, Fulvio, Di Veroli, Ambra, Anaclerico, Barbara, Colafigli, Gioia, Molica, Matteo, Spadea, Antonio, Petriccione, Luca, Cimino, Giuseppe, and Latagliata, Roberto
- Published
- 2017
- Full Text
- View/download PDF
9. Catheter-associated bloodstream infections and thrombotic risk in hematologic patients with peripherally inserted central catheters (PICC)
- Author
-
Morano, Salvatore Giacomo, Latagliata, Roberto, Girmenia, Corrado, Massaro, Fulvio, Berneschi, Paola, Guerriero, Alfonso, Giampaoletti, Massimo, Sammarco, Arianna, Annechini, Giorgia, Fama, Angelo, Di Rocco, Alice, Chistolini, Antonio, Micozzi, Alessandra, Molica, Matteo, Barberi, Walter, Minotti, Clara, Brunetti, Gregorio Antonio, Breccia, Massimo, Cartoni, Claudio, Capria, Saveria, Rosa, Giovanni, Alimena, Giuliana, and Foà, Robin
- Published
- 2015
- Full Text
- View/download PDF
10. Syringomyelia Associated with Chiari 1 Malformation in Adults: Positive Outcome Predictors after Posterior Fossa Decompression with Duraplasty.
- Author
-
Ciaramitaro, Palma, Migliaretti, Giuseppe, Ferraris, Marilena, Garnero, Andrea, Morana, Giovanni, Carucci, Paolo, Stura, Ilaria, Massaro, Fulvio, and Garbossa, Diego
- Subjects
ARNOLD-Chiari deformity ,SYRINGOMYELIA ,POSTOPERATIVE pain ,ADULTS ,CRANIOVERTEBRAL junction ,ANALGESIA ,SYMPTOMS ,CEREBROSPINAL fluid shunts - Abstract
Background: Syringomyelia (Syr) in patients with Chiari 1 malformation (CM1) may be attributable to abnormal dynamics of cerebrospinal fluid (CSF) in the upper cervical segment; fourth ventricle enlargement has been reported in association with a worse clinical and radiological presentation, independently of the posterior fossa volume. In this study, we analyzed presurgery hydrodynamic markers to evaluate if their changes could be associated with clinical and radiological improvement after posterior fossa decompression and duraplasty (PFDD). As a primary endpoint, we aimed to correlate improvement in the fourth ventricle area with positive clinical outcomes. Methods: In total, in this study, we enrolled 36 consecutive adults with Syr and CM1 who were followed by a multidisciplinary team. All the patients were prospectively evaluated with clinical scales and neuroimaging, including CSF flow, the fourth ventricle area, and the Vaquero Index by using a phase-contrast MRI before (T0) and after surgical treatment (T1-Tlast, with a range of 12–108 months). The CSF flow at the craniocervical junction (CCJ), the fourth ventricle area, and the Vaquero Index changes were statistically analyzed and compared to the clinical and quality of life improvement after surgery. The good outcome prediction ability of presurgical radiological variables was tested. Results: Surgery was associated with positive clinical and radiological outcomes in more than 90% of cases. The fourth ventricle area significantly reduced after surgery (T0-Tlast, p = 0.0093), but no significant associations with clinical improvement were found. The presurgical presence of CSF flow at the CCJ was able to predict a good outcome (AUC = 0.68, 95% CI 0.50–0.87 and LH+ = 2.1, IC 95% 1.16–3.07) and was also significantly associated with post-surgical pain relief (rho = 0.61 and p = 0.0144). Conclusions: Presurgery CSF flow at the CCJ is proposed as a radiological marker with the ability to predict a positive outcome after PFDD in adults with syringomyelia and CM1. Measurements of the fourth ventricle area could be useful additional information for evaluating surgical long-term follow-up; further experience on larger cohorts is required to better define the prognostic yield of this radiological parameter. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
11. New Perspectives in Treating Acute Myeloid Leukemia: Driving towards a Patient-Tailored Strategy.
- Author
-
Andreozzi, Fabio, Massaro, Fulvio, Wittnebel, Sebastian, Spilleboudt, Chloé, Lewalle, Philippe, and Salaroli, Adriano
- Subjects
- *
ACUTE myeloid leukemia , *OLDER patients , *AZACITIDINE , *DRUG accessibility , *VENETOCLAX - Abstract
For decades, intensive chemotherapy (IC) has been considered the best therapeutic option for treating acute myeloid leukemia (AML), with no curative option available for patients who are not eligible for IC or who have had failed IC. Over the last few years, several new drugs have enriched the therapeutic arsenal of AML treatment for both fit and unfit patients, raising new opportunities but also new challenges. These include the already approved venetoclax, the IDH1/2 inhibitors enasidenib and ivosidenib, gemtuzumab ozogamicin, the liposomal daunorubicin/cytarabine formulation CPX-351, and oral azacitidine. Venetoclax, an anti BCL2-inhibitor, in combination with hypomethylating agents (HMAs), has markedly improved the management of unfit and elderly patients from the perspective of improved quality of life and better survival. Venetoclax is currently under investigation in combination with other old and new drugs in early phase trials. Recently developed drugs with different mechanisms of action and new technologies that have already been investigated in other settings (BiTE and CAR-T cells) are currently being explored in AML, and ongoing trials should determine promising agents, more synergic combinations, and better treatment strategies. Access to new drugs and inclusion in clinical trials should be strongly encouraged to provide scientific evidence and to define the future standard of treatment in AML. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real‐life experience.
- Author
-
Massaro, Fulvio, Pavone, Vincenzo, Stefani, Piero Maria, Botto, Barbara, Pulsoni, Alessandro, Patti, Caterina, Cantonetti, Maria, Visentin, Andrea, Scalzulli, Potito Rosario, Rossi, Andrea, Galimberti, Sara, Cimminiello, Michele, Gini, Guido, Musso, Maurizio, Sorio, Marco, Arcari, Annalisa, Zilioli, Vittorio Ruggero, Luppi, Mario, Mannina, Donato, and Fabbri, Alberto
- Subjects
STEM cell transplantation ,HODGKIN'S disease ,DISEASE relapse ,PROGRESSION-free survival ,SALVAGE therapy - Abstract
The standard management for relapsed or refractory classical Hodgkin lymphoma (cHL) is salvage therapy followed by autologous stem cell transplantation (ASCT). This strategy allows almost 50% of patients to be cured. Post‐ASCT maintenance treatment with brentuximab vedotin (BV) confers improved progression‐free survival (PFS) to cHL patients at high risk of relapse. We investigated the outcome of 105 cHL patients receiving post‐ASCT BV maintenance in the real‐life setting of 23 Italian hematology centers. This population included naïve patients and those previously exposed to BV. Median follow‐up was 20 months. Patients presented a median of two lines of treatment pre‐ASCT, with 51% receiving BV. Twenty‐nine percent of patients had at least two high‐risk factors (refractory disease, complete response [CR] less than 12 months, extranodal disease at relapse), while 16% presented none. At PET‐CT, a Deauville score (DS) of 1–3 was reported in 75% and 78% of pre‐ and post‐ASCT evaluations, respectively. Grade 3–4 adverse events (AEs), mainly peripheral neuropathy, were observed in 16% of patients. Three‐year PFS and overall survival (OS) were 62% and 86%, respectively. According to BV exposure, 3‐year PFS and OS were 54% and 71%, respectively, for naïve and 77% and 96%, respectively, for previously exposed patients. Refractory disease (hazard ratio [HR] 4.46; p = 0.003) and post‐ASCT DS 4–5 (HR 3.14; p = 0.005) were the only two factors significantly associated with PFS reduction in multivariable analysis. Post‐ASCT BV maintenance is an effective, safe treatment option for cHL naïve patients and those previously exposed to BV. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
13. Long‐term results of the MCL01 phase II trial of rituximab plus HyperCVAD alternating with high‐dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma.
- Author
-
Massaro, Fulvio, Stepanishyna, Yana, Manni, Martina, Luminari, Stefano, Galimberti, Sara, Marcheselli, Luigi, Visco, Carlo, Tecchio, Cristina, Stelitano, Caterina, Angrilli, Francesco, Petrini, Mario, Merli, Francesco, and Federico, Massimo
- Subjects
- *
RITUXIMAB , *METHOTREXATE , *CYTARABINE , *STEM cell transplantation , *LYMPHOPROLIFERATIVE disorders , *MANTLE cell lymphoma , *CASTLEMAN'S disease - Abstract
Summary: Mantle cell lymphoma is a rare and incurable lymphoproliferative disorder. In the MCL01 trial, patients were treated with the R‐HCVAD regimen [rituximab plus HyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone; R‐CVAD) alternating with high‐dose methotrexate and cytarabine (AM)] for four cycles followed by autologous stem cell transplantation (ASCT) for those who reached only a partial response. After a median follow‐up of 10·5 years, we reported 10‐year progression‐free and overall survival rates of 35% and 61% respectively, with a 10‐years cumulative incidence rate of second malignancies of 10·6%. Mature results of the MCL01 trial confirmed the efficacy of HyperCVAD‐AM as a frontline regimen for younger patients (≤65 years). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Management of Extramedullary Intradural Spinal Tumors: The Impact of Clinical Status, Intraoperative Neurophysiological Monitoring and Surgical Approach on Outcomes in a 12-Year Double-Center Experience.
- Author
-
Cofano, Fabio, Giambra, Carlotta, Costa, Paolo, Zeppa, Pietro, Bianconi, Andrea, Mammi, Marco, Monticelli, Matteo, Di Perna, Giuseppe, Junemann, Carola Vera, Melcarne, Antonio, Massaro, Fulvio, Ducati, Alessandro, Tartara, Fulvio, Zenga, Francesco, and Garbossa, Diego
- Subjects
INTRAOPERATIVE monitoring ,NEUROPHYSIOLOGIC monitoring ,LAMINECTOMY ,SURGICAL excision ,SPINAL canal ,SURGICAL complications ,TUMORS - Abstract
Objective: Intradural Extramedullary (IDEM) tumors are usually treated with surgical excision. The aim of this study was to investigate the impact on clinical outcomes of pre-surgical clinical conditions, intraoperative neurophysiological monitoring (IONM), surgical access to the spinal canal, histology, degree of resection and intra/postoperative complications. Methods: This is a retrospective observational study analyzing data of patients suffering from IDEM tumors who underwent surgical treatment over a 12 year period in a double-center experience. Data were extracted from a prospectively maintained database and included: sex, age at diagnosis, clinical status according to the modified McCormick Scale (Grades I-V) at admission, discharge, and follow-up, tumor histology, type of surgical access to the spinal canal (bilateral laminectomy vs. monolateral laminectomy vs. laminoplasty), degree of surgical removal, use and type of IONM, occurrence and type of intraoperative complications, use of Ultrasonic Aspirator (CUSA), radiological follow-up. Results: A total number of 249 patients was included with a mean follow-up of 48.3 months. Gross total resection was achieved in 210 patients (84.3%) mostly in Schwannomas (45.2%) and Meningiomas (40.4%). IONM was performed in 162 procedures (65%) and D-wave was recorded in 64.2% of all cervical and thoracic locations (99 patients). The linear regression diagram for McCormick grades before and after surgery (follow-up) showed a correlation between preoperative and postoperative clinical status. A statistically significant correlation was found between absence of worsening of clinical condition at follow-up and use of IONM at follow-up (p = 0.01) but not at discharge. No associations were found between the choice of surgical approach and the extent of resection (p = 0.79), the presence of recurrence or residual tumor (p = 0.14) or CSF leakage (p = 0.25). The extent of resection was not associated with the use of IONM (p = 0.91) or CUSA (p = 0.19). Conclusion: A reliable prediction of clinical improvement could be made based on pre-operative clinical status. The use of IONM resulted in better clinical outcomes at follow-up (not at discharge), but no associations were found with the extent of resection. The use of minimally invasive approaches such as monolateral laminectomy showed to be effective and not associated with worse outcomes or increased complications. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Germinotropic lymphoproliferative disorder: a systematic review.
- Author
-
Zanelli, Magda, Zizzo, Maurizio, Bisagni, Alessandra, Froio, Elisabetta, De Marco, Loredana, Valli, Riccardo, Filosa, Alessandra, Luminari, Stefano, Martino, Giovanni, Massaro, Fulvio, Fratoni, Stefano, and Ascani, Stefano
- Subjects
LYMPHOPROLIFERATIVE disorders ,CASTLEMAN'S disease ,SCIENTIFIC literature ,META-analysis ,KAPOSI'S sarcoma ,NOCARDIOSIS ,DIFFUSE large B-cell lymphomas - Abstract
Germinotropic lymphoproliferative disorder is a rare and rather enigmatic novel entity with distinctive clinicopathological features, one of which is the typical co-infection by Human herpesvirus 8 and Epstein-Barr virus. Human herpesvirus 8 is a lymphotropic virus detected in Kaposi sarcoma, multicentric Castleman disease, primary effusion lymphoma, Human herpesvirus 8-positive diffuse large B cell lymphoma not otherwise specified, and germinotropic lymphoproliferative disorder. Co-infection by Human herpesvirus 8 and Epstein-Barr virus is identified only in two lymphoproliferative diseases: germinotropic lymphoproliferative disorder and primary effusion lymphoma, which are otherwise diseases with totally different clinical presentations and outcomes. Unlike primary effusion lymphoma mostly occurring in immunocompromised individuals and following an aggressive course, germinotropic lymphoproliferative disorder usually presents with single or multiple lymphadenopathy affecting mainly immunocompetent individuals and mostly follows an indolent course. Based on the PRISMA guidelines, we carried out a systematic search on PubMed/MEDLINE, Web of Science, Scopus, EMBASE, and Cochrane Library using the search terms "germinotropic" and "lymphoproliferative disorder." Current scientific literature reports just 19 cases of germinotropic lymphoproliferative disorder. The purpose of our systematic review is to improve our understanding of the disease, focusing on epidemiology, clinical presentation, pathological features, treatment, and outcome. In addition, we discuss the differential diagnosis with the other Human herpesvirus 8-related lymphoproliferative diseases as currently recognized in the World Health Organization classification, adding a focus on lymphoproliferative disorders showing overlapping features. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Incidence of Clinically Significant (≤10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib.
- Author
-
Cesini, Laura, Carmosino, Ida, Breccia, Massimo, De Benedittis, Daniela, Mohamed, Sara, De Luca, Maria Lucia, Colafigli, Gioia, Molica, Matteo, Scalzulli, Emilia, Massaro, Fulvio, Mariggiò, Elena, Rizzo, Lorenzo, Loglisci, Maria Giovanna, Scamuffa, Maria Cristina, Vozella, Federico, Diverio, Daniela, Mancini, Marco, Alimena, Giuliana, Foà, Robin, and Latagliata, Roberto
- Subjects
CHRONIC myeloid leukemia ,OLDER patients ,IMATINIB ,ANEMIA ,ERYTHROCYTES ,CHRONIC leukemia - Abstract
Background: In elderly patients with chronic myeloid leukemia (CML) responsive to imatinib, the incidence of clinically significant (CS) late chronic anemia is still unknown. Materials and Methods: To highlight this issue, we revised retrospectively 81 CML patients aged >60 years treated at our Institution with front-line imatinib for at least 24 months in durable complete cytogenetic response (CCyR). CS late chronic anemia was defined as the presence of persistent (>6 months) and otherwise unexplained Hb levels ≤10 g/dL, which occurred >6 months from imatinib start. Results: A condition of CS late chronic anemia occurred in 22 out of 81 patients (27.2%) at different intervals from imatinib start. Seven out of 22 patients (31.8%) needed packed red cell transfusions during the follow-up. At diagnosis, patients who developed CS late chronic anemia were significantly older and had a lower Hb median level. Six out of 22 patients with CS late chronic anemia received subcutaneous recombinant alpha-erythropoietin (EPO) at the standard dosage of 40,000 IU weekly: all 6 patients achieved an erythroid response. A significantly worse event-free survival (EFS) in patients with untreated CS late chronic anemia was observed (p = 0.012). Conclusions: CS late chronic anemia during long-term treatment with imatinib is a common complication in responsive elderly patients, with worse EFS if untreated. Results with EPO are encouraging, but larger studies are warranted to define its role. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse?.
- Author
-
Latagliata, Roberto, Breccia, Massimo, Carmosino, Ida, Cesini, Laura, Benedittis, Daniela, Mohamed, Sara, Vozella, Federico, Molica, Matteo, Campanelli, Melissa, Luca, Maria Lucia, Colafigli, Gioia, Quattrocchi, Luisa, Loglisci, Maria Giovanna, Massaro, Fulvio, Canichella, Martina, Diverio, Daniela, Mancini, Marco, Alimena, Giuliana, and Foà, Robin
- Subjects
MYELOID leukemia ,BONE marrow diseases ,IMATINIB ,CYTOGENETICS ,NONLYMPHOID leukemia - Abstract
Objectives: To evaluate differences in clinical results according to age among patients with chronic myeloid leukemia (CML). Methods: 207 consecutive CML patients treated with imatinib frontline were revised, dividing them in young adults (>20 < 45 years) (YA), middle‐aged adults (≥45 < 65 years) (MA) and elderly (≥65 years) (EL). Results: Cumulative incidence of complete cytogenetic response (CCyR) and major molecular response (MMolR) were significantly higher in MA compared with YA and EL (P < .001 for CCyR and P = .001 for MMolR). Number of total events was lower in MA (8 [11.1%] vs 21 [34.4%] in YA and 28 [37.8%] in EL, P = .001): no difference was observed for blastic evolution (P = .478). Number of deaths was higher in the EL (12 [16.2%] vs 2 [3.2%] in YA and 0 in MA, P < .001): however, 11/12 deaths in EL were not related to CML. The PFS curve in MA was significantly longer than in YA and in EL (P = .02). The OS curve in EL was significantly shorter than in YA and in MA (P < .001). Conclusions: Age at diagnosis influences significantly the course of CML patients treated with imatinib: a possible explanation of the counterintuitive worse course in YA is the delayed diagnosis compared to elderly. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
18. Long‐term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib.
- Author
-
Molica, Matteo, Breccia, Massimo, Colafigli, Gioia, Massaro, Fulvio, Quattrocchi, Luisa, Mancini, Marco, Diverio, Daniela, Latagliata, Roberto, and Foà, Robin
- Subjects
CHRONIC myeloid leukemia ,IMATINIB ,GENETIC mutation ,ANTINEOPLASTIC agents ,DRUG resistance - Abstract
The article presents a study that investigated if a pattern of molecular response (MR) instability could affect overall survival (OS) and failure-free survival in a series of chronic myeloid leukaemia(CP-CML) patients who received imatinib for a median follow-up of 7 years. Topics discussed include analysis of the patients for mutational screening with Sanger sequencing analysis and the association of MR3 with increased probability of developing resistance to imatinib.
- Published
- 2018
- Full Text
- View/download PDF
19. Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy.
- Author
-
Massaro, Fulvio, Colafigli, Gioia, Molica, Matteo, and Breccia, Massimo
- Published
- 2018
- Full Text
- View/download PDF
20. Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update.
- Author
-
Molica, Matteo, Massaro, Fulvio, and Breccia, Massimo
- Abstract
Introduction: Despite the advent of molecular assessment, banding cytogenetics and fluorescencein situhybridization (FISH) still have a significant role in diagnostic and prognostic approaches to chronic myeloid leukaemia (CML). Area covered: At diagnosis and during treatment with tyrosine kinase inhibitors (TKIs), cytogenetics is used to detect the Philadelphia chromosome, with its typical translocation t(9;22)(q34;q11.2), and any additional or other chromosomal aberrations (ACAs and OCAs) that may arise in 5–10% of cases, the latter associated to transformation of the disease in blast phases. In this review, the potential role of banding cytogenetics and FISH is discussed through a review of published papers on the prognostic impact of these tools in CML treatment and monitoring. Expert commentary: Cytogenetic techniques, including banding cytogenetics and FISH, continue to maintain a crucial role in CML monitoring. At diagnosis and after 3 months of therapy, banding cytogenetics will continue to be an essential test to perform, but it will become redundant after the achievement of a major molecular response (MMR) assessed with molecular techniques. FISH analysis maintains its usefulness in monitoring the response to TKIs only in special situations. [ABSTRACT FROM PUBLISHER]
- Published
- 2017
- Full Text
- View/download PDF
21. How ruxolitinib modified the outcome in myelofibrosis: focus on overall survival, allele burden reduction and fibrosis changes.
- Author
-
Massaro, Fulvio, Molica, Matteo, and Breccia, Massimo
- Published
- 2017
- Full Text
- View/download PDF
22. Severe Thrombotic Complications in Congenital Afibrinogenemia: A Pathophysiological and Management Dilemma.
- Author
-
Santoro, Cristina, Massaro, Fulvio, Venosi, Salvatore, Capria, Saveria, Baldacci, Erminia, Foà, Roberto, and Mazzucconi, Maria Gabriella
- Subjects
- *
CONGENITAL disorders , *PATHOLOGICAL physiology , *DISEASE complications , *BLOOD platelets , *FIBRINOGEN , *ANTITHROMBINS , *PLASMIN - Abstract
Congenital afibrinogenemia (CA) is a disease characterized by a complex pathophysiology, involving both the procoagulant and fibrinolytic systems, as well as platelet activity. Although hemorrhagic diathesis represents the most frequent clinical presentation of this disorder, severe thrombotic events can occur. It is not yet clear if these events are strictly related to the disease itself or to the fibrinogen replacement therapy. Different hypotheses on the pathophysiological mechanisms have been proposed. It is well known that fibrinogen/fibrin has a role in the downregulation of thrombin generation in plasma. In the absence of circulating fibrinogen, this "antithrombin" activity is missing and plasma thrombin levels rise; this excess of thrombin could promote clotting of the infused fibrinogen, initiating the thrombotic process. Furthermore, the observation of impaired plasmin generation in the plasma of CA patients has raised the hypothesis of a fibrinolytic system deficiency. We report the case of a CA male patient who at the age of 36 years experienced an arterial thrombosis in his left lower limb. Despite an aggressive medical treatment with low-molecular-weight heparin, fibrinolytic and antiplatelet agents, the arterial thrombosis progressed to the obstruction of the whole left arterial district and the patient underwent the amputation of the left lower limb. This case demonstrates the complexity of pathophysiology and clinical management of a "so- called" bleeding disorder as CA. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
23. Life-Threatening Autoimmune Hemolytic Anemia and Idhiopatic Thrombocytopenic Purpura. Successful Selective Splenic Artery Embolization.
- Author
-
Molica, Matteo, Massaro, Fulvio, Annechini, Giorgia, Baldacci, Erminia, D'Elia, Gianna Maria, Rosati, Riccardo, Trisolini, Silvia Maria, Volpicelli, Paola, Foà, Robin, and Capria, Saveria
- Subjects
- *
THERAPEUTIC embolization , *HYPERSPLENISM , *EMBOLISMS - Abstract
Selective splenic artery embolization (SSAE) is a nonsurgical intervention characterized by the transcatheter occlusion of the splenic artery and/or its branch vessels using metallic coils or other embolic devices. It has been applied for the management of splenic trauma, hypersplenism with portal hypertension, hereditary spherocytosis, thalassemia and splenic hemangioma. We hereby describe a case of a patient affected by idiopathic thrombocytopenic purpura (ITP) and warm auto-immune hemolytic anemia (AIHA) both resistant to immunosuppressive and biological therapies, not eligible for a surgical intervention because of her critical conditions. She underwent SSAE and achieved a hematologic complete response within a few days without complications. SSAE is a minimally invasive procedure to date not considered a standard option in the management of AIHA and ITP. However, following the progressive improvement of the techniques, its indications have been extended, with a reduction in morbidity and mortality compared to splenectomy in patients with critical clinical conditions. SSAE was a lifesaving therapeutic approach for our patient and it may represent a real alternative for the treatment of resistant AIHA and ITP patients not eligible for splenectomy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
24. The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials.
- Author
-
Molica, Matteo, Canichella, Martina, Alunni Fegatelli, Danilo, Colafigli, Gioia, Massaro, Fulvio, Latagliata, Roberto, Foà, Robin, and Breccia, Massimo
- Published
- 2017
- Full Text
- View/download PDF
25. Brentuximab Vedotin and Pembrolizumab Combination in Patients with Relapsed/Refractory Hodgkin Lymphoma: A Single-Centre Retrospective Analysis.
- Author
-
Massaro, Fulvio, Meuleman, Nathalie, Bron, Dominique, Vercruyssen, Marie, and Maerevoet, Marie
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *HODGKIN'S disease , *DISEASE progression , *COMBINATION drug therapy , *CANCER chemotherapy , *CANCER relapse , *RETROSPECTIVE studies , *HEMATOPOIETIC stem cell transplantation , *SALVAGE therapy - Abstract
Simple Summary: The standard treatment for Hodgkin lymphoma (HL) patients presenting a relapsed/refractory (R/R) disease is salvage chemotherapy followed by autologous stem cell transplantation (ASCT). With commonly used chemotherapy combinations, 25–30% fail to proceed to ASCT, with poor outcomes. The aim of this retrospective study was to evaluate the efficacy of brentuximab vedotin (BV) and pembrolizumab combination as a bridge to ASCT in R/R HL patients. We retrospectively collected data from 10 patients, 8 male and 2 female, with a median age of 30.7 years. The median follow-up time was 16.5 months, while the median number of received cycles of treatment was 4 (2–7). Eight patients proceeded to ASCT (80%) and seven of them to subsequent BV maintenance, with two early disease progression (PD). The BV and pembrolizumab combination is a very effective bridge treatment to ASCT for high-risk R/R HL patients. Classical Hodgkin lymphoma (HL) patients presenting a relapsed/refractory (R/R) disease are currently managed with salvage chemotherapy followed by autologous stem cell transplantation (ASCT). However, almost 25–30% of these patients fail to achieve a complete response (CR) with standard salvage regimens. In this retrospective study, we evaluated the efficacy of a combination of brentuximab vedotin (BV) and pembrolizumab in a series of HL patients presenting with a high-risk, multi-refractory disease. Patients achieving a Deauville score ≤4 proceeded to ASCT consolidation. After ASCT, patients received BV as maintenance for a total of 16 administrations. We collected data from 10 patients with a median age of 30.7 years. At a median follow-up of 16.5 months, we reported a complete metabolic remission (CMR) in eight patients (80%), with seven patients (70%) directly proceeding to ASCT (the other two patients in CMR are still undergoing treatment). BV consolidation was started in six patients and completed by three patients (one ongoing, two interruption). Two patients (20%) presented a progressive disease (PD) and subsequently died, while the others are still in CMR. The BV and pembrolizumab combination is a very effective bridge treatment to ASCT for high-risk R/R HL patients. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
26. Aging of Bone Marrow Mesenchymal Stromal Cells: Hematopoiesis Disturbances and Potential Role in the Development of Hematologic Cancers.
- Author
-
Massaro, Fulvio, Corrillon, Florent, Stamatopoulos, Basile, Meuleman, Nathalie, Lagneaux, Laurence, and Bron, Dominique
- Subjects
- *
DISEASE progression , *CELL communication , *STEM cells , *HEMATOLOGIC malignancies , *AGING , *BONE marrow , *HEMATOPOIESIS , *DISEASE risk factors - Abstract
Simple Summary: As for many other cancers, the risk of developing hematologic malignancies increases considerably as people age. In recent years, a growing number of studies have highlighted the influence of the aging microenvironment on hematopoiesis and tumor progression. Mesenchymal stromal cells are a major player in intercellular communication inside the bone marrow microenvironment involved in hematopoiesis support. With aging, their functions may be altered, leading to hematopoiesis disturbances which can lead to hematologic cancers. A good understanding of the mechanisms involved in mesenchymal stem cell aging and the consequences on hematopoiesis and tumor progression is therefore necessary for a better comprehension of hematologic malignancies and for the development of therapeutic approaches. Aging of bone marrow is a complex process that is involved in the development of many diseases, including hematologic cancers. The results obtained in this field of research, year after year, underline the important role of cross-talk between hematopoietic stem cells and their close environment. In bone marrow, mesenchymal stromal cells (MSCs) are a major player in cell-to-cell communication, presenting a wide range of functionalities, sometimes opposite, depending on the environmental conditions. Although these cells are actively studied for their therapeutic properties, their role in tumor progression remains unclear. One of the reasons for this is that the aging of MSCs has a direct impact on their behavior and on hematopoiesis. In addition, tumor progression is accompanied by dynamic remodeling of the bone marrow niche that may interfere with MSC functions. The present review presents the main features of MSC senescence in bone marrow and their implications in hematologic cancer progression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
27. Author Index.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.